Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

CD4 down-modulating compounds with potent anti-HIV activity.

Kurt Vermeire¹, Dominique Schols, Thomas W Bell

¹Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium. kurt.vermeire@rega.kuleuven.ac.be

Current Pharmaceutical Design

|June 8, 2004

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Impact of Plasticizer Polarity on the Permeability of Hydroxypropyl Methylcellulose Phthalate Films.

Molecular pharmaceutics·2026

Same author

The development of biologically contained Sudan virus as an alternative and safe tool for fundamental filovirus research.

Emerging microbes & infections·2026

Same author

Discovery of 1-(3-phenoxybenzyl)-4-(1-phenyl-1H-1,2,3-triazol-4-yl)piperidine analogues as potent and selective agonists of the human CC chemokine receptor 8.

European journal of medicinal chemistry·2026

Same author

Integrated omics reveal a unique antibacterial mechanism of action for the small molecule HSI#6.

Current research in microbial sciences·2026

Same author

High-Affinity Nanobody Against the LEDGF PWWP Domain Inhibits Chromatin Binding In Vitro.

Biomolecules·2026

Same author

Membrane-Permeable Nucleoside T-1106 Diphosphate and Triphosphate Analogues as Antiviral Pronucleotides.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026

Same journal

Fentanyl and its Analogs: A Medicinal Chemistry Perspective on Therapeutic Potential and Abuse Liability.

Current pharmaceutical design·2026

Same journal

Acne Vulgaris: Integrating Pathophysiology with Conventional, Herbal, and Nanocarrier-Based Therapeutic Strategies.

Current pharmaceutical design·2026

Same journal

Systems Pharmacology and Pharmaco-Transcriptomic Insights into Bauhinia variegata for Polycystic Ovary Syndrome Management.

Current pharmaceutical design·2026

Same journal

Curcumin and Cognitive Health: Insights from Randomized Controlled Trials.

Current pharmaceutical design·2026

Same journal

Inorganic Materials-integrated Porphyrin for Drug Delivery in Cancer Therapy: Promises, Challenges and Outlooks.

Current pharmaceutical design·2026

Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026

See all related articles

New anti-HIV drugs are crucial due to resistance and side effects. This research explores novel entry inhibitors, focusing on cyclotriazadisulfonamides (CADA), which target HIV entry by modulating CD4 receptors.

Area of Science:

Virology
Immunology
Pharmacology

Background:

Highly active antiretroviral therapy (HAART) has improved AIDS survival but faces challenges like drug resistance and side effects.
Understanding HIV-1 entry, a complex process involving viral attachment, coreceptor interactions, and fusion, is key to developing new therapies.
Enfuvirtide (T-20), a successful entry inhibitor, validates targeting HIV entry as a vital antiretroviral strategy.

Purpose of the Study:

To review recent developments in therapeutic agents inhibiting HIV entry.
To highlight novel compounds targeting the interaction between HIV envelope glycoprotein gp120 and the CD4 receptor.
To focus on the anti-HIV activity and unique mechanism of cyclotriazadisulfonamides (CADA).

Main Methods:

Review of recent scientific literature on HIV entry inhibitors.

Related Experiment Videos

Analysis of therapeutic agents targeting gp120-CD4 binding.

Examination of cyclotriazadisulfonamides (CADA) and their mechanism of action.

Main Results:

Several agents inhibiting gp120-CD4 binding, including PRO 542, BMS-378806, TNX-355, PRO 2000, and CV-N, have been developed.
Cyclotriazadisulfonamides (CADA) represent a novel class of compounds with significant anti-HIV activity.
CADA function by down-modulating the CD4 receptor on lymphocytic and monocytic cells.

Conclusions:

Targeting HIV entry is a promising strategy for developing new antiretroviral therapies.
Novel entry inhibitors, such as CADA, offer unique mechanisms to combat HIV infection.
Further development of entry inhibitors is encouraged by the success of agents like enfuvirtide and the potential of compounds like CADA.